We are international
Donate
• webcasts   TEXT SIZE   
webcasts from medical meetings

ASH 2005 Webcast - Stem Cell Harvesting Using GCSF Alone
By Dr. Ravi Vij
12.29.05
Stem Cell Harvesting Using GCSF Alone



 related articles
High-Dose Melphalan in the Era of New Effective Agents
The Potential Role of Novel Combinations in Frontline Therapy
The Importance of Achieving Complete Remission (CR)
Does the Percentage of Complete Response with New Drugs Determine Ultimate Survival?
The Safety Issue Surrounding Maintenance Therapy
Does Maintenance Therapy Improve Time to Progression and Ultimate Survival?
Is Double Transplant Better Than Single Transplant?
Tandem vs Single Transplant: Which is Better for Whom?
Role of New Drug Trials at Relapse
ASH 2005 Webcast


You might also be interested in:

What is role of high-dose melphalan in the era of new effective agents?
High-Dose Melphalan in the Era of New Effective Agents
Bart Barlogie, MD
University of Arkansas for Medical Sciences
Myeloma Institute for Research and Therapy
Little Rock, Arkansas

The Potential Role of Novel Combinations in Frontline Therapy
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California

Does the percentage of complete response with new drugs determine ultimate survival?
The Importance of Achieving Complete Remission (CR)
James D. Cavenagh, MD, MRCP
St. Bartholomew's Hospital
London, England

Does the Percentage of Complete Response with New Drugs Determine Ultimate Survival?
Jean-Luc Harousseau, MD
University Hospital Nantes
Nantes, France

Does maintenance improve time to progression and ultimate survival?
The Safety Issue Surrounding Maintenance Therapy
Antonio Palumbo, MD
Molinette Hospital
Turin, Italy

Does Maintenance Therapy Improve Time to Progression and Ultimate Survival?
James D. Cavenagh, MD MRCP
St. Bartholomew's Hospital
London, England

Is double transplant better than single transplant?
Is Double Transplant Better Than Single Transplant?
Jean-Luc Harousseau, MD
University Hospital Nantes
Nantes, France

Tandem vs Single Transplant: Which is Better for Whom?
Bart Barlogie, MD
University of Arkansas for Medical Sciences
Myeloma Institute for Research and Therapy
Little Rock, Arkansas

Should known effective therapies or new agents be used in patients with relapsed disease?
Role of New Drug Trials at Relapse
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California

ASH 2005 Webcast
The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2005 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.